http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2007147594-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 |
| filingDate | 2006-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2007147594-A |
| titleOfInvention | COMBINATIONS OF INDOVATEROL DERIVATIVES AND OTHER AGENTS FOR TREATMENT OF RESPIRATORY DISEASES |
| abstract | 1. A medicine comprising, individually or in combination (A), a compound of formula I! ! in free form or in salt or solvate form, where! W means a group of the formula! ! Rx and Ry both mean -CH2- or - (CH2) 2-,! R1 is hydrogen, hydroxy or C1-C10 alkoxy! R2 and R3 each independently mean hydrogen or C1-C10 alkyl,! R4, R5, R6 and R7 each independently mean hydrogen, halogen, cyano, hydroxy, C1-C10 alkoxy, C6-C10 aryl, C1-C10 alkyl, C1-C10 alkyl substituted with one or more halogen atoms or one or more hydroxy or C1-C10 alkoxy groups , C1-C10 alkyl interrupted by one or more heteroatoms, C2-C10 alkenyl, trialkylsilyl, carboxy, C1-C10 alkoxycarbonyl or -CONR11R12, where! R11 and R12 each independently mean hydrogen or C1-C10 alkyl, or! R4 and R5, R5 and R6 or R6 and R7 together with the carbon atoms to which they are attached mean a 5-, 6- or 7-membered carbocyclic ring or a 4-10-membered heterocyclic ring, a! R8, R9 and R10 each independently mean hydrogen or C1-C4 alkyl, and! (B) one or more compounds that are selected from the group consisting of! (1) A2A agonists,! (2) A2B antagonists,! (3) antihistamines,! (4) caspase inhibitors,! (5) ENaC inhibitors,! (6) LTB4 antagonists,! (7) LTD4 antagonists and! (8) serine protease inhibitors,! for simultaneous, sequential or separate administration in the treatment of inflammatory or obstructive airway disease. ! 2. The drug according to claim 1, which is a pharmaceutical composition comprising a mixture of an effective amount of component (A) and component (B) optionally in a mixture with at least one pharmaceutically acceptable carrier. ! 3. The drug according to claim 1, in which component (A) means a compound |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2449991-C2 |
| priorityDate | 2005-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.